Prot #NU MSK12H10: A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients with Relapsed or Refractory Hairy Cell Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date7/9/147/9/17

Funding

  • Genentech, Inc. (Prot #NU MSK12H10)
  • Memorial Sloan-Kettering Cancer Center (Prot #NU MSK12H10)